2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
11
Breast Neoplasms
8
Prostatic Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
5
Melanoma
5
COVID-19
4
Multiple Myeloma
3
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Recurrence
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Leukemia
2
Glioblastoma
2
Cholangiocarcinoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Urologic Diseases
1
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma, Clear Cell
1
Sarcoma
1
Interventions
Adalimumab
19
Etanercept
16
Methotrexate
11
Infliximab
8
tocilizumab
7
Rituximab
7
golimumab
6
Abatacept
6
tofacitinib
5
Tumor Necrosis Factor Inhibitors
5
olokizumab
4
Certolizumab Pegol
4
Antirheumatic Agents
3
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Arthritis, Rheumatoid
×
Hydroxychloroquine
×
Clear all
NCT03449758
2022-04-28
SariPRO
Sanofi
Phase 4
Completed
84 enrolled
36 charts